A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 01 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2014 Planned End Date changed from 1 Mar 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 20 Feb 2014 Planned End Date changed from 1 Dec 2012 to 1 Mar 2014, as per ClinicalTrials.gov record.